NovoCure's Share-based Compensation fell 651.38% to $29.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was $147.8 million, marking a year-over-year increase of 2881.64%. This contributed to the annual value of $160.0 million for FY2024, which is 3842.9% up from last year.
Latest data reveals that NovoCure reported Share-based Compensation of $29.3 million as of Q3 2025, which was down 651.38% from $26.1 million recorded in Q2 2025.
In the past 5 years, NovoCure's Share-based Compensation ranged from a high of $62.8 million in Q4 2024 and a low of $17.4 million during Q4 2023
In the last 5 years, NovoCure's Share-based Compensation had a median value of $27.9 million in 2021 and averaged $29.6 million.
Its Share-based Compensation has fluctuated over the past 5 years, first plummeted by 4144.79% in 2023, then soared by 25988.65% in 2024.
Over the past 5 years, NovoCure's Share-based Compensation (Quarter) stood at $22.4 million in 2021, then surged by 32.97% to $29.8 million in 2022, then plummeted by 41.45% to $17.4 million in 2023, then soared by 259.89% to $62.8 million in 2024, then plummeted by 53.28% to $29.3 million in 2025.
Its last three reported values are $29.3 million in Q3 2025, $26.1 million for Q2 2025, and $29.6 million during Q1 2025.

Peer Comparison

Historic Data

Download Data 🔒

Date	Value